187 related articles for article (PubMed ID: 34107346)
1. Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.
Martin JE; Khalife-Hachem S; Grinda T; Kfoury M; Garciaz S; Pasquier F; Vargaftig J; Uzunov M; Belhabri A; Bertoli S; Cotteret S; Vergé V; Renneville A; Rosselli F; Antony-Debre I; Rouleau E; Salviat F; Caron O; Delaloge S; Pautier P; Etienne G; Recher C; Vey N; De Botton S; Leary A; Marzac C; Micol JB
Ann Oncol; 2021 Aug; 32(8):1046-1048. PubMed ID: 34107346
[No Abstract] [Full Text] [Related]
2. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
3. Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Response.
Marmouset V; Morice PM; Pagès A; Leary A; Micol JB
Clin Cancer Res; 2023 Mar; 29(6):1158-1159. PubMed ID: 36916192
[No Abstract] [Full Text] [Related]
4. Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Letter.
Batalini F; Mina LA; Mina A
Clin Cancer Res; 2023 Mar; 29(6):1157. PubMed ID: 36916193
[No Abstract] [Full Text] [Related]
5. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
6. [Poly (ADP-Ribose) Polymerase Inhibitors--Current Status and Future Developments].
Yoshida H; Fujiwara K
Gan To Kagaku Ryoho; 2016 Feb; 43(2):193-7. PubMed ID: 27093730
[No Abstract] [Full Text] [Related]
7. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours.
Almanza-Huante E; Bataller A; Urrutia S; Gener-Ricos G; Briski RE; Kanagal-Shamanna R; Lu KH; Westin SN; Yap TA; Takahashi K; Ravandi F; Alvarado Y; Kadia T; Sasaki K; Kantarjian HM; Garcia-Manero G
Br J Haematol; 2023 May; 201(3):e25-e29. PubMed ID: 36951293
[No Abstract] [Full Text] [Related]
8. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Pommier Y; O'Connor MJ; de Bono J
Sci Transl Med; 2016 Oct; 8(362):362ps17. PubMed ID: 27797957
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
10. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
11. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase inhibition: past, present and future.
Curtin NJ; Szabo C
Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
14. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
15. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
Shah AP; Patel CN; Sureja DK; Sanghavi KP
Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
[TBL] [Abstract][Full Text] [Related]
16. Poly (ADP-ribose) polymerase inhibitors in cancer treatment.
Mason KA; Raju U; Buchholz TA; Wang L; Milas ZL; Milas L
Am J Clin Oncol; 2014 Feb; 37(1):90-100. PubMed ID: 22495455
[TBL] [Abstract][Full Text] [Related]
17. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
18. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer.
Liu CH; Chang Y; Wang PH
Taiwan J Obstet Gynecol; 2017 Oct; 56(5):713-714. PubMed ID: 29037569
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
